恶性肿瘤与高纤维蛋白原血症  

Malignant tumor and hyperfibrinogenemia

作　　者：刘秀巧[1] 王淑娟[2] 吴振茹[2] 孙巍[1] 万文徽[1] 

机构地区：[1]北京大学临床肿瘤学院北京市肿瘤医院检验科,100036 [2]北京大学第一医院

出　　处：《中华肿瘤杂志》2002年第1期51-52,共2页Chinese Journal of Oncology

摘　　要：目的　通过监测血浆纤维蛋白原 (FIB)含量 ,研究其在治疗及预后评估中的临床意义。方法　采用ACL 2 0 0血凝分析仪对 43例恶性肿瘤患者化疗前后的血浆进行FIB测定。结果　恶性肿瘤患者的FIB水平较非恶性肿瘤患者显著升高 ;部分化疗后好转的恶性肿瘤患者 ,治疗后的FIB水平较治疗前显著下降 ;复发转移的恶性肿瘤患者FIB水平再次升高。结论　FIB在辅助诊断恶性肿瘤、监测疗效及评估预后方面对临床有一定的指导意义。Objective To investigate the blood fibrinogen (FIB) content before and after chemotherapy or radiotherapy in 43 malignant tumor patients.Methods COULTER ACL-200 automated coagulation analyzer was used in monitoring FIB in the patients.Results The FIB content was significantly higher in malignant tumor patients than that in benign disease patients. Significant reduction was observed after treatment which became elevated again when there was recurrence or metastasis.Conclusion Assessment of FIB not only helps to diagnose cancers but evaluate the therapeutic effect and prognosis also.

关 键 词：血液 血浆纤维蛋白原 高纤维蛋白原血症 恶性肿瘤 诊断 治疗 

分 类 号：R730.2[医药卫生—肿瘤]